Spin-off - Inhibrx Biosciences, Inc.

Form Type: 10-K

Filing Date: 2025-03-17

Corporate Action: Spin-off

Type: Update

Accession Number: 000200791925000019

Filing Summary: Inhibrx Biosciences, Inc. completed a significant spin-off from its former parent company, Inhibrx, Inc. In January 2024, the former parent announced the creation of Inhibrx as an independent entity focused on its therapeutic pipeline. On May 29, 2024, the former parent executed a distribution that transferred 92% of Inhibrx's shares to its common stockholders. This was succeeded by a merger involving Inhibrx's former parent and a subsidiary of Aventis Inc. on May 30, 2024. Following this merger, Inhibrx inherited specific assets and liabilities related to ongoing projects like INBRX-106 and ozekibart (INBRX-109). As part of the spin-off, stockholders received cash payments and additional rights associated with the new entity. Inhibrx continues to operate autonomously, advancing clinical trials for its therapeutic candidates that target various cancers and aims for future regulatory submissions.

Document Link: View Document